1. A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. (12th December 2018) Authors: Van Horebeek, Lies; Hilven, Kelly; Mallants, Klara; Van Nieuwenhuijze, Annemarie; Kelkka, Tiina; Savola, Paula; Mustjoki, Satu; Schlenner, Susan M; Liston, Adrian; Dubois, Bénédicte; Goris, An Journal: Human molecular genetics Issue: Volume 28:Number 8(2019) Page Start: 1369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti‐cytokine autoantibodies are rare in chronic graft‐versus‐host disease. (6th July 2021) Authors: Sarkkinen, Joona; Lundgren, Sofie; Itälä‐Remes, Maija; Salmenniemi, Urpu; Mustjoki, Satu; Peterson, Pärt; Kekäläinen, Eliisa Journal: Scandinavian journal of immunology Issue: Volume 94:Number 3(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (NordCML006). (13th September 2014) Authors: Hjorth‐Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde‐Dahl, Tobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Waleed; Markevärn, Berit; Ohm, Lotta; Olsson‐Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Be... Journal: European journal of haematology Issue: Volume 94:Number 3(2015:Mar.) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Issue 6 (June 2018) Authors: Saussele, Susanne; Richter, Johan; Guilhot, Joelle; Gruber, Franz X; Hjorth-Hansen, Henrik; Almeida, Antonio; Janssen, Jeroen J W M; Mayer, Jiri; Koskenvesa, Perttu; Panayiotidis, Panayiotis; Olsson-Strömberg, Ulla; Martinez-Lopez, Joaquin; Rousselot, Philippe; Vestergaard, Hanne; Ehrencrona, Han... Journal: Lancet oncology Issue: Volume 19:Issue 6(2018) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response. (28th January 2014) Authors: Koskenvesa, Perttu; Kreutzman, Anna; Rohon, Peter; Pihlman, Markus; Vakkila, Emmi; Räsänen, Anu; Vapaatalo, Mirja; Remes, Kari; Lundán, Tuija; Hjorth‐Hansen, Henrik; Vakkila, Jukka; Simonsson, Bengt; Mustjoki, Satu; Porkka, Kimmo Journal: European journal of haematology Issue: Volume 92:Number 5(2014:May) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. (2nd September 2019) Authors: Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore; Hee Lee, Moon; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjorth-Hansen, He... Journal: Oncoimmunology Issue: Volume 8:Number 9(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy. Issue 4 (April 2014) Authors: Ilander, Mette; Koskenvesa, Perttu; Hernesniemi, Sari; Lion, Thomas; Porkka, Kimmo; Mustjoki, Satu Journal: Leukemia & lymphoma Issue: Volume 55:Issue 4(2014:Apr.) Page Start: 934 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study. (31st August 2021) Authors: Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Mustjoki, Satu; Majeed, Waleed; Lübking, Anna; Dreimane, Arta; Markevärn, Berit; Stenke, Leif; Myhr Eriksson, Kristina; Gjertsen, Bjørn Tore; Gedde‐Dahl, Tobias; Dimitrijevic, Andreja; Udby, Lene; Olsson‐Ström... Journal: European journal of haematology Issue: Volume 107:Number 6(2021) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Issue 9 (21st March 2016) Authors: Schiffer, Charles A.; Cortes, Jorge E.; Hochhaus, Andreas; Saglio, Giuseppe; le Coutre, Philipp; Porkka, Kimmo; Mustjoki, Satu; Mohamed, Hesham; Shah, Neil P. Journal: Cancer Issue: Volume 122:Issue 9(2016) Page Start: 1398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies. (7th March 2020) Authors: Halkola, Anni S.; Parvinen, Kalle; Kasanen, Henna; Mustjoki, Satu; Aittokallio, Tero Journal: Journal of theoretical biology Issue: Volume 488(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗